Sugi Predict

Sugi Predict / Compounds / SCHEMBL223559

SCHEMBL223559

SCHEMBL223559

COc1cc(S(=O)(=O)N2CCOCC2)ccc1N

nearest known ligand 0.71

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.71
▸ KDM4E B2RXH2 3/20 0.67
▸ LMNA P02545 1/20 0.67
▸ HSD17B10 Q99714 2/20 0.61
▸ TSHR P16473 1/20 0.61
▸ CASP1 P29466 1/20 0.61
▸ SMN1; SMN2 Q16637 2/20 0.58
▸ POLB P06746 2/20 0.57
▸ USP2 O75604 1/20 0.57
▸ MAPK1 P28482 1/20 0.56
▸ GPBAR1 Q8TDU6 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ GAA P10253 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17373976 0.89 KDM4E (0.71) ALDH1A1KDM4ELMNAHSD17B10TSHR
SCHEMBL22233113 0.88 ALDH1A1 (0.57) ALDH1A1KDM4ELMNAHSD17B10TSHR
SCHEMBL29483631 0.87 KDM4E (0.77) ALDH1A1KDM4ELMNAHSD17B10TSHR
SCHEMBL16480610 0.84 ALDH1A1 (0.73) ALDH1A1KDM4ELMNAHSD17B10TSHR
SCHEMBL1491825 0.84 L3MBTL1 (0.72) ALDH1A1KDM4ELMNAHSD17B10TSHR
SCHEMBL9996945 0.83 KDM4E (0.80) ALDH1A1KDM4ELMNAHSD17B10TSHR
SCHEMBL23997044 0.82 ALDH1A1 (0.70) ALDH1A1KDM4ELMNAHSD17B10TSHR
SCHEMBL8262953 0.82 ALDH1A1 (0.76) ALDH1A1KDM4ELMNAHSD17B10TSHR
SCHEMBL12970680 0.82 ALDH1A1 (0.65) ALDH1A1KDM4ELMNAHSD17B10TSHR
SCHEMBL5627956 0.81 SMN1; SMN2 (0.69) ALDH1A1KDM4ELMNAHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2507243-B1 SPIROINDOLINONE PYRROLIDINES HOFFMANN LA ROCHE (CH) 2015-06-10 — — EP claimed
EP-2507243-A1 SPIROINDOLINONE PYRROLIDINES F. Hoffmann-La Roche AG (CH) 2012-10-10 — — EP claimed
CN-119968361-A Compounds targeting p 53Y 220 mutants 北京加科思新药研发有限公司 2025-05-09 — — CN disclosed
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-12-05 — — US disclosed
EP-4384510-A1 COMPOUNDS TARGETING MUTANT OF P53 Jacobio Pharmaceuticals Co., Ltd. (CN) 2024-06-19 — — EP disclosed
CN-117813295-A Compounds targeting p53 mutants 北京加科思新药研发有限公司 2024-04-02 — — CN disclosed
WO-2024041503-A1 COMPOUNDS TARGETING Y220C MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-02-29 — — WO disclosed
US-11814373-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-14 — — US disclosed
US-11814373-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-14 — — US disclosed
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-10-05 — — US disclosed
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-10-05 — — US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 — — US disclosed
EP-2507243-B1 SPIROINDOLINONE PYRROLIDINES HOFFMANN LA ROCHE (CH) 2015-06-10 — — EP disclosed
US-20130217664-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2013-08-22 — — US disclosed
US-20130217664-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2013-08-22 — — US disclosed
WO-2013117645-A1 IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2013-08-15 — — WO disclosed
EP-2507243-A1 SPIROINDOLINONE PYRROLIDINES F. Hoffmann-La Roche AG (CH) 2012-10-10 — — EP disclosed
US-8088815-B2 Spiroindolinone pyrrolidines HOFFMAN-LA ROCHE INC. (US) 2012-01-03 — — US disclosed
WO-2011067185-A1 SPIROINDOLINONE PYRROLIDINES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-09 — — WO disclosed
US-20110130398-A1 SPIROINDOLINONE PYRROLIDINES BARTKOVITZ DAVID JOSEPH 2011-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK ALDH1A1 4333/4885KDM4E 1662/4885LMNA 3015/4885
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS ALDH1A1 1538/4885KDM4E 2994/4885LMNA 2920/4885
US-20130217664-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES JAK1, IL6, JAK3 ALDH1A1 1175/4885KDM4E 3158/4885LMNA 3782/4885
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 TP53, TP53BP1, MDM2 ALDH1A1 2527/4885KDM4E 4363/4885LMNA 922/4885
US-11814373-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS ALDH1A1 1538/4885KDM4E 2994/4885LMNA 2920/4885
US-20110130398-A1 SPIROINDOLINONE PYRROLIDINES RPS4Y1, RB1, RPS4X ALDH1A1 416/4885KDM4E 1458/4885LMNA 1998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.